Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma

Oncology (Switzerland)

Volumn 85, Issue 4, 2013, Pages 197-203

  Kaseb, Ahmed O ^a   Shama, Mohamed ^a   Sahin, Ibrahim Halil ^a   Nooka, Ajay ^e   Hassabo, Hesham M ^a   Vauthey, Jean Nicolas ^b   Aloia, Thomas ^b   Abbruzzese, James L ^a   Subbiah, Ishwaria M ^c   Janku, Filip ^d   Curley, Steven ^b   Hassan, Manal M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Departments of Surgical Oncology   (United States)

^c Division of Cancer Medicine   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrolamellar carcinoma; Hepatocellular carcinoma; Recurrence free survival; Survival

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; INTERFERON; PAZOPANIB; RAPAMYCIN; SORAFENIB; SUNITINIB; TRASTUZUMAB; VALPROIC ACID; VORINOSTAT; ALPHA FETOPROTEIN; PROTEASOME INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; FEMALE; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; ALPHA FETOPROTEIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CARCINOMATOSIS; CLINICAL FEATURE; LIVER CIRRHOSIS; LIVER GRAFT; MINIMAL RESIDUAL DISEASE; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; SYSTEMIC THERAPY;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888234954     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000354698     Document Type: Article

References (18)

1. Edmondson HA: Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 1956; 91: 168-186.
2. Berman MM, Libbey NP, Foster JH: Hepatocellular carcinoma. Polygonal cell type with fibrous stroma-an atypical variant with a favorable prognosis. Cancer 1980; 46: 1448-1455.
3. Craig JR, Peters RL, Edmondson HA, Omata ML: Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980; 46: 372-379.
4. El-Serag HB, Davila JA: Is fibrolamellar carcinoma different from hepatocellular carcinoma A US population-based study. Hepatology 2004; 39: 798-803.
5. Curutchet HP, Terez JJ, Kay S, Lawrence W Jr: Primary liver cancer. Surgery 1971; 70: 467-479.
6. el-Domeiri AA, Huvos AG, Goldsmith HS, Foote FW Jr: Primary malignant tumors of the liver. Cancer 1971; 27: 7-11.
7. Malt RA, Van Vroonhoven TY, Kakumoto Y: Manifestations and prognosis of carcinoma of the liver. Surg Gynecol Obstet 1972; 135: 361-364.
8. Moreno-Luna LE, Arrieta O, Garcia-Leiva J, Martinez B, Torre A, Uribe M, Leon-Rodriguez E: Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer 2005; 5: 142.
9. Torbenson M: Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 2007; 14: 217-223.
10. Liu S, Chan KW, Wang B, Qiao L: Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol 2009; 104: 2617-2624, quiz 2625.
11. Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD: Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005; 18: 1417-1423.
12. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002.
13. Malouf GG, Brugieres L, Le Deley MC, et al: Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer 2012; 118: 4981-4990.
14. Katzenstein HM, Krailo MD, Malogolowkin MH, et al: Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003; 97: 2006-2012.
15. El-Gazzaz G, Wong W, El-Hadary MK, et al: Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int 2000; 13(suppl 1):S406-S409.
16. Ang CS, Kelley RK, Choti MA, et al: Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res 2013; 6: 3-9.
17. Eggert T, McGlynn KA, Duffy A, et al: Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut 2013, E-pub ahead of print.
18. Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21: 421-427.